An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
| Dr. John M. Carethers Elected to AACR Board of Directors
Moores Cancer Center (MCC) Member and Vice Chancellor for Health Sciences at UC San Diego, John M. Carethers, M.D., has been elected a Member of the American Association for Cancer Research (AACR), Board of Directors for the 2023–2026 term.
|
|
|
Stem Cell Role in Aging and Age-Related Diseases
The unique ability of stem cells to recycle mis-folded proteins could be key to long-term health and longevity, according to a new study from Dr. Robert Signer's lab at the UC San Diego, School of Medicine.
|
|
|
ARPA-H Signals It Is Open for Business with a Range of New Initiatives
One year ago, President Biden outlined his vision for a new kind of agency to speed medical breakthroughs to patients who urgently need them, calling for the creation of the Advanced Research Projects Agency for Health (ARPA-H). Last week, President Biden reaffirmed that commitment with the release of the budget, which calls for additional funding for the agency.
To mark this milestone, on March 15 2023, ARPA-H announced a series of firsts that serve the agency’s mission of accelerating better health outcomes, which include support of the Cancer Moonshot initiative. Specifically, ARPA-H has issued its first funding opportunities through an agency-wide Open Broad Agency Announcement (Open BAA) and an idea competition called the “ARPA-H Dash,” in addition to releasing its site selection strategy.
For more information, see these ARPA-H announcements:
|
|
|
In-Person MCC Structural and Functional Genomics (SFG) Cross Lab Meetings to Resume, Starting April 12, 2023
Starting Wednesday April 12, 2023, in-person SFG Cross-Lab Meetings will resume. All in-person SFG Cross-Lab Meetings will be held in alternating locations (i.e., Leichtag, each 2nd Wednesday of the month; Comer Commons, each 4th Wednesday of the month) at 12:00 p.m.
SFG is excited for in-person interaction and looks forward to your participation. Lunch, light refreshments, and coffee will be served.
|
|
|
Join the MCC Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
Biotech Companies, Investors Pour Billions into mRNA Vaccines as Research Ramps Up in Cancer and Non-Communicable Diseases
Read full article on page 5 of The Cancer Letter, volume 49, issue 11.
Women’s History Month: Ernestine Hambrick’s Contributions to Colorectal Cancer Surgery
Read full article on page 38 of The Cancer Letter, volume 49, issue 11.
|
|
|
| Pharmacology Seminar Series
Self-assemblies in Transcriptional Regulation: Aire and FoxP3
Tuesday, March 28, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
Optional Webinar Registration
Sun Hur, Ph.D.
Senior Investigator, Program in Cellular and Molecular Medicine
Children’s Hospital Boston
HHMI Investigator and Oscar M. Schloss Professor
Department of Pediatrics
Department of Biological Chemistry and Molecular Pharmacology
Harvard Medical School
Hosted by Anjana Rao, Ph.D.
|
|
|
|
Pharmacology Seminar Series (Co-organized by Cell Signaling San Diego)
Licence to Kill: Understanding How the Zombie Protein, MLKL, Is Triggered to Kill Cells by Necroptosis
Thursday, March 30, 2023 at 2:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
Optional Webinar Registration
James Murphy, Ph.D.
Professor and Head
Division of Inflammation
Walter and Eliza Hall Institute of Medical Research, Australia
Hosted by Susan Taylor, Ph.D.
|
|
|
| Solid Tumor Therapeutics Seminar
Unconventional Signaling of CD28 and CTLA4: When Their Ligands Get on T Cells
Friday, April 21, 2023 from 12:00 to 12:45 p.m. PT
MCC Comer Commons
Zoom Link
Enfu Hui, Ph.D.
Associate Professor
Department of Cell and Developmental Biology
School of Biological Sciences
UC San Diego
|
|
|
Looking for One or Two Postdocs to Participate on the Cancer Biology Training Consortium (CABTRAC) Planning Committee
The meeting will be held in Newport Beach, CA, October 22-24, 2023. For more information, see this link: https://cab-trac.org/
If interested in being part of the Planning Committee, then email Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu and provide her with your CV and a brief paragraph that explains why you are interested in this opportunity.
|
|
|
Student Volunteers Available for Spring Quarter, Beginning April 3, 2023
MCC Cancer Research, Training, Education, and Coordination (CRTEC) has identified a number of enthusiastic UC San Diego undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab.
If you are interested in a student volunteer, then please complete the REDCap form below for CRTEC to match you with an appropriate student.
https://redcap.link/lebsyfcm
Students can begin volunteering at the beginning Spring Quarter 2023, which begins this year on Monday, April 3, 2023.
Please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu with any questions that you may have about this opportunity.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC CRTEC. These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
SITC Fellowships: Funding Opportunities for Early Career Scientists
The Society for Immunotherapy of Cancer (SITC) is committed to assisting young investigators in advancing the science of immunotherapy. This year, the SITC Forward Fund is pleased to offer four SITC Fellowships, totaling $440,000. The due date is upon us (March 27, 2023), so submit your application today!
SITC Fellowships are only available to SITC members. Not a member? Sign up today.
Deadline: Monday, March 27, 2023
|
| |
NIH Instrumentation Grant (S10) Programs: Institutional Coordination Required
Institutional coordination is required for all S10 requests. Investigators intending to submit an NIH shared instrumentation proposal for the June 2023 deadline must submit an internal LOI by the stated deadline to avoid potential overlap.
Applications received after the internal deadline are subject to review and may be confirmed to submit to the NIH only if the proposed instrument does not overlap with a proposal that was submitted by the internal deadline. The Office of Research Affairs will provide the mandatory institutional performance table for all applicants.
This internal call covers two companion NIH funding opportunities to support high-priced research instruments that (1) can be justified only on a shared-use basis and (2) are needed for NIH-supported projects in basic, translational, and clinical biomedical or bio-behavioral research. Programs provide funds to purchase or upgrade a single expensive, specialized, commercially available instrument or integrated system.
|
-
Under the Shared Instrumentation Grant (SIG) Program (PAR-22-080), the minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000.
-
Under the High-End Instrumentation (HEI) Grant Program (PAR-22-079), the minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000.
|
Eligibility/Requirements
Although the PD/PI need not possess an NIH research grant or any other research support, he or she is expected to be an expert on the requested instrument. The PI may be a core director or tenured or non-tenured faculty member of the applicant organization. Multiple PIs are not allowed.
Applications must identify at least three "major users" who exhibit a "substantial need" for the instrument. Each of these users must be a PI on a distinct active NIH research award in an area of basic, translational, or clinical research. NIH training or fellowship grants, other non-research and SBIR/STTR grants, or other transaction (OT) awards and contracts cannot be counted toward the fulfillment of this requirement.
Resources
For complete details, please view the individual announcements for the Shared Instrumentation Grant and the High-End Instrumentation Grant. Applicants are advised to discuss with the relevant Scientific/Research Contact any questions about appropriate types of equipment, eligibility, and program requirements.
A list of recent awards and FAQs can be viewed on the S10 website.
Resources for preparing instrumentation grants, which include a list of recurring funding opportunities that support equipment purchases, can be found on the internal Research Development website (SSO login required with @ucsd.edu form of campus credentials).
|
- Internal submission deadline: Tuesday, March 28, 2023 at 5:00 p.m.
- Funding organization deadline: Thursday, June 1, 2023
- Project Period: 1 year
-
Program website: https://orip.nih.gov/construction-and-instruments/s10-instrumentation-programs
- Sponsor reference number: PAR-22-079; PAR-22-080
- Cost-share or match required: No
- Amount note: Budgets vary by program
- Funding organization: NIH (ORIP, NIGMS, NIMH)
|
If you plan to apply for either the Shared or High-End Instrumentation Grant Program (S10), please submit the following information via ucsd.infoready4.com by the internal deadline:
|
- Instrument model. Provide the exact name of the requested instrument, including manufacturer and model.
-
Location. Provide the name of the building and core facility in which the instrument will be placed.
-
Brief justification. Why is this instrument needed at UC San Diego? If similar instrumentation is available on campus, then why it is not accessible to the requesting team? (3-5 sentences)
- Users. Which departments or areas of campus will the instrument serve? Include the names of three required and confirmed Major Users. (2-3 sentences)
|
Deadline: Tuesday, March 28, 2023 at 5:00 p.m.
Questions? Contact Lynsey Fitzpatrick (email)
|
|
|
Department of Defense (DOD), Ovarian Cancer Research Program (OCRP), Clinical Trial Award (CTA)
The DOD Congressionally Directed Medical Research Program (CDMRP) will allot approximately $6.4M to fund one to three CTA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTA should not exceed $2.0M.
The DOD CDMRP OCRP CTA supports the rapid implementation of clinical trials with the potential to heavily influence the treatment or management of ovarian cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, phase 0 trials) to demonstrate the feasibility or inform the design of more advanced trials to large-scale trials to determine efficacy in relevant patient populations.
Required Pre-Application Submission Deadline: Saturday, May 26, 2023
|
|
|
DOD OCRP Clinical Translational Research Award (CTRA)
The DOD CDMRP will allot approximately $3.2M to fund one to two CTRA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTRA should not exceed $2.0M.
The DOD CDMRP OCRP CTRA supports correlative studies that are associated with a clinical trial (past, ongoing, or future) to correlate various factors (genetic, biochemical, environmental, and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis, or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. Although not all-inclusive, research proposed under this mechanism may entail initiation of a deeper molecular analysis of clinical samples, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis testing or may be designed to generate clinically annotated and molecularly characterized experimental platforms (e.g., tissue arrays and patient-derived models). The award may not be used to directly support a clinical trial.
Required Pre-Application Submission Deadline: Sunday, May 26, 2023
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Notice of Special Interest (NOSI): Administrative Supplements for NCI Division of Cancer Biology (DCB) Research Programs
You may submit applications for this initiative using any of the 24 funding opportunity announcements (FOAs) listed on the website above or any reissues of these announcement through the expiration date of this notice.
Through this NOSI, current awardees of DCB-led programs can apply for supplemental funding to support collaborative research projects. DCB-led or DCB-co-led programs appropriate for this NOSI include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.
Deadline: April 20, 2023
|
|
|
NOSI: Administrative Supplements to Examine the Effects of Digital Tools and Interventions on Patient-provider Communication across the Cancer Control Continuum
Applications for this NOSI must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-272.
This NOSI encourages currently funded NCI extramural investigators to apply for administrative supplements to better understand the effects of digital health tools and interventions on patient-provider communication across the cancer control continuum, with the aim of developing an evidence base to inform future development, modification, and delivery of digital tools and/or interventions for effective cancer prevention and control.
Deadline: April 21, 2023
|
|
|
2023 Bayer-Prostrate Cancer Foundation (PCF) Health Equity Research Awards for Health Equity Implementation Research for Patients with Prostate Cancer
Award provides up to a total of $200K/year per team over 2 years. Approximately $500K is designated for this award mechanism.
The PCF and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Health Equity Research Awards for novel health equity implementation research projects with the goal of reducing racial and ethnic disparities in the diagnosis and treatment of advanced prostate cancer. These awards will be funded, depending on the level of innovation in applications received. PCF and Bayer seek high-risk, currently unfunded projects from academic institutions in only the United States.
LOI Submission Deadline: Friday, May 5, 2023 at 3:00 p.m. ET
Application Submission Deadline: Monday, July 10, 2023 at 3:00 p.m. ET
|
|
|
Robert A. Winn, Diversity in Clinical Trials Career Development Award (Winn CDA) for Early-Stage Investigator Physicians
The Winn CDA provides $120K/year for 2 years to protect 40% of the awardee's work time for program participation.
The Winn CDA is a 2-year program designed to support the career development of early-stage investigator (ESI) physicians (as defined by NIH) who are underrepresented in medicine (URM) or who have a demonstrated commitment to increasing diversity in clinical research. The program prepares participants to become independent clinical trial investigators engaged in advancing health equity through their research and mentoring. The goal of the Winn CDA is to transform the clinical research landscape by building and strengthening partnerships between clinical investigators and the communities in which their patients reside to ultimately engage a patient population that mirrors the epidemiology of the disease studied.
Winn CDA Scholar Eligibility Criteria
|
-
Must identify as a racial/ethnic group designated as “underrepresented in medicine” OR have a demonstrated commitment to increasing diverse patient participation in clinical trials.
- Must be a U.S. Citizen, Lawful Permanent Resident, or hold an H-1B or O-1 Visa.
- Must hold the degree of M.D., M.D./Ph.D., D.O., or D.O./Ph.D.
-
Must engage in one of the following clinical research areas: cancer (hematology and oncology), cardiovascular disease, or immunologic disorders.
- Must be an early-stage investigator (ESI).
-
Must be mentored by an experienced clinical investigator at an established clinical trial site and participate substantively in the mentor's active clinical trial (it is not expected that scholars will have their own clinical trials).
|
At the start of the program, Winn CDA Scholars participate in a 5.5-day intensive workshop: Design and Implementation of Clinical Trials. Then, over the course of 2 years, Winn CDA Scholars engage in a Community-Oriented Clinical Trialist curriculum that is designed to train a new generation of first-rate clinical trialists with the additional knowledge, skills, and competencies to effectively engage with communities to foster active community participation in clinical and translational research.
Informational Webinar: Tuesday, March 28, 2023 at 3:00 p.m. ET (Register Here)
Deadline: Friday, May 12, 2023
|
|
|
NOSI: Administrative Supplement to Support Health Policy Research in Cancer Prevention and Control
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-272
This NOSI encourages currently funded NCI extramural investigators to apply for administrative supplements to support cancer-related policy research, which features empirical evaluation of policy or evaluation of policy implementation or dissemination methods.
Deadline: April 21, 2023
|
|
NOSI: Administrative Supplements to Conduct Systematic Evidence Reviews on the Clinical Utility of Cancer Site-specific Polygenic Risk Scores (PRS) for Cancer Risk Assessment
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-272
This NOSI encourages currently funded NCI extramural investigators to apply for administrative supplements to (1) conduct systematic evidence reviews that assess the state of the science on the clinical utility of cancer site-specific polygenic risk scores for cancer risk assessment and (2) inform future trials and research directions for clinical translation and implementation.
Deadline: April 23, 2023
|
| Provision of Training and Technical Assistance to Enhance Comprehensive Cancer Control Outcomes
This multi-component NOFO will fund up to three recipients with national reach, cancer expertise, and capacity to provide training and technical assistance on multisectoral partnerships; policy, system, and environmental change approaches; health equity change; and social determinants of change approaches to National Comprehensive Cancer Control Program (NCCCP) recipients and cancer coalitions.
Deadline: May 8, 2023
|
|
|
Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)
Application budgets should reflect the actual needs of the proposed project but must not exceed $700,000 in direct costs per year. The maximum project period is 5 years.
This Funding Opportunity Announcement (FOA) will support the development and testing of primary care practice (PCP)- and health system-level interventions and strategies to promote high quality care for adult cancer survivors during and/or after cancer treatment.
Deadline: June 30, 2023
|
| NOSI: Research on the Etiology, Early Detection, Screening, and Prevention of Early-Onset Colorectal Cancer
This NOSI applies to due dates on or after January 5, 2023 and subsequent receipt dates through July 2, 2025. You may submit applications for this initiative using any of the 30 FOAs listed on the website below or any reissues of these announcement through the expiration date of this notice.
|
| NOSI: Administrative Supplement to Support Global Cancer Stigma Research
Applications can be submitted on a rolling basis between January 16, 2023 and May 21, 2023 at 5:00 p.m. local time of applicant organization for FY 2023 funding. Applications for this initiative must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
|
|
NOSI: Career Development Opportunities for Research within the Mission of the NCI Division of Cancer Prevention (DCP)
This NOSI applies to due dates on or after February 12, 2023, and subsequent receipt dates through November 13, 2024.
|
| NOSI: Technology Development for Cancer Control and Population Science Research.
This NOSI applies to due dates on or after March 1, 2023 and subsequent receipt dates through the expiration date of this notice.
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
|
|
Department of Defense (DOD) Ovarian Cancer, Investigator-Initiated Research Award
Amounts from $300K to $800K; pre-application required; due date April 17, 2023.
Deadline: July 21, 2023
|
| DOD Lung Cancer Translational Research Award
Amounts from $375K to $1.2M; pre-application required; due dates May 2 and May 10, 2023.
Deadline: August 3, 2023
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
|
|
NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
A budget for direct costs of up to $50,000 per year may be requested; maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
The combined budget for direct costs for the 2-year maximum project period may not exceed $275,000; no more than $200,000 may be requested in any single year.
Deadline: Standard NIH deadlines apply
|
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
|
|
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are limited to $600,000 direct costs (excluding consortium F&A) per year; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| NOSI: Adaptive Biomaterials for Cancer Biology
This NOSI invites applications that propose the development of advanced biomaterials for use in fundamental cancer biology research and proposals incorporating the novel application of advanced biomaterials to address cancer biology research questions.
Deadline: Standard NIH deadlines apply
|
| |
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
Postdoctoral Positions in Cancer Research
The laboratory of Dr. Thomas Kipps at MCC is seeking highly qualified and motivated postdoctoral fellows (scientists) to participate in state-of-the-art translational cancer research projects to investigate the genetics and immunology of cancer development and the generation of novel pharmacologic cancer therapeutics.
The Kipps laboratory investigates novel therapeutics for patients with leukemia and solid tumors. A particular focus of the laboratory is the function of onco-embryonic antigens, such as ROR1, which are selectively expressed by tumor cells and that contribute to malignant behavior. This involves the development and testing of novel agents that can target such antigens and/or their associated signaling pathways that contribute to the survival, growth, metastatic potential, and/or cancer stemness of neoplastic cells, even in the setting of conventional anti-cancer therapy. These studies can result in the development of more-effective therapies for patients with cancer.
Applicants for these postdoctoral positions must possess a Ph.D., strong analytical skills, proficiency in oral and written scientific presentations, and a demonstrated commitment to a career in cancer research.
These postdoctoral positions are offered preferably to candidates who have recently received their Ph.D. or have completed 3 years or less of post graduate education.
If interested, then submit a cover letter, curriculum vitae, statement of research interests, and the names and contact information of three references to Beth Lipski at elipski@ucsd.edu.
|
|
|
SITC Advances in Cancer Immunotherapy: A Focus on Lung Cancers
Thursday, April 6, 2023 from 12:00 p.m. to 4:00 p.m.
San Diego and Virtual
Free for healthcare professionals, students, patients, and patient advocates, this Advances in Cancer Immunotherapy program is CME-, CNE-, CPE- and MOC-certified and will be presented by leading authorities in tumor immunology and cancer immunotherapy. The program will provide the latest updates in immunotherapy for lung cancers and address practical applications, immune-related adverse events, and future trends.
|
|
|
Structural and Functional Genomics (SFG) Program Retreat
Friday, May 5, 2023
MCC Goldberg Auditorium and Lobby
Breakfast and lunch will be provided.
|
|
|
Joseph Califano, M.D.
Director, MCC
Director, Gleiberman Head & Neck Cancer Center
Professor, Department of Otolaryngology/Head & Neck Surgery UCSD, School of Medicine
Co-Leader, MCC, SFG Program
|
| Jill P. Mesirov, Ph.D.
Associate Vice Chancellor for Computational Health Sciences
Professor, Department of Medicine
UCSD, School of Medicine
Co-Leader, MCC, SFG Program
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
Newly Opened Clinical Trials
|
|
|
EA8191: Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients With Post-Prostatectomy Biochemical Recurrence
PI: Randall, J
NCT: NCT04423211
|
| | |
|
SGNTUC-028: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2 Breast Cancer (HER2CLIMB05)
PI: Yeung, K
NCT: NCT05132582
|
| | |
|
SHARED RESOURCE SPOTLIGHT
|
|
|
MCC Tissue Technology Shared Resource (TTSR) Receives Accreditation from the College of American Pathologists (CAP)
The CAP Accreditation Committee has awarded accreditation to the MCC TTSR, based on results of a recent on-site inspection as part of CAP's Accreditation Programs.
TTSR Director, Alfredo Molinolo, M.D., Ph.D., was advised of this national recognition and congratulated for the excellence of the services being provided. The MCC TTSR lab is one of more than 8,000 CAP-accredited facilities worldwide.
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program.
During the CAP accreditation process, which is designed to ensure the highest standards of care for all laboratory patients, inspectors examine a given laboratory's records and quality control of procedures for the preceding 2 years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, peruse the CAP Annual Report: https://www.cap.org/
|
|
|
-
Kim JW, McKay RR (STT), Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: The results from National Cancer Institute 9984. J Clin Oncol. 2023 FEB 01.
- Luo W, Adamska JZ, Li C, Verma R, Liu Q, Hagan T, Wimmers F, Gupta S, Feng Y, Jiang W, Zhou J, Valore E, Wang Y, Trisal M, Subramaniam S (SFG), Osborne TF, Pulendran B. SREBP signaling is essential for effective B cell responses. Nat Immunol. 2023 FEB 01.
-
Loomba R (CCP), Huang DQ, Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Ding D, Ma L, Jia C, Billin A, Huss RS, Chung C, Goodman Z, Wong VW, Okanoue T, Romero-Gómez M, Abdelmalek MF, Muir A, Afdhal N, Bosch J, Harrison S, Younossi ZM, Myers RP. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut. 2023 MAR 01.
-
Contadini C, Ferri A, Di Martile M, Cirotti C, Del Bufalo D, De Nicola F, Pallocca M, Fanciulli M, Sacco F, Donninelli G, Capone A, Volpe E, Keller N, Miki S, Kawauchi D, Stupack D (STT), Furnari F (CBS), Barilà D. Caspase-8 as a novel mediator linking Src kinase signaling to enhanced glioblastoma malignancy. Cell Death Differ. 2023 FEB 01.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to this newsletter, please make use of the newsletter submission form that is linked below. In order to submit to our newsletter submission form, you must be logged into Google with your UC San Diego email account.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie at sjchristie@health.ucsd.edu
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The current 480 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and cancer-risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. Holding Comprehensive status since 2001, MCC was founded in 1977 by John Mendelsohn and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to .
To continue receiving our emails, add us to your address book.
|
|
|
|
